MARKET

AUPH

AUPH

Aurinia Pharmace
NASDAQ
15.72
+0.49
+3.22%
After Hours: 15.72 0 0.00% 16:10 05/11 EDT
OPEN
15.35
PREV CLOSE
15.23
HIGH
16.05
LOW
15.14
VOLUME
2.18M
TURNOVER
--
52 WEEK HIGH
16.88
52 WEEK LOW
7.29
MARKET CAP
2.02B
P/E (TTM)
7.26
1D
5D
1M
3M
1Y
5Y
1D
Aurinia Pharmaceuticals Completes Acquisition of Kezar Life Sciences
TipRanks · 9h ago
FDA's Makary On Brink: Why Biotech And Pharma Investors Shouldn't Panic (Or Celebrate)
Seeking Alpha · 9h ago
Aurinia completes Kezar acquisition at $6.96 per share plus CVR
PUBT · 10h ago
Bloom Burton Keeps Their Hold Rating on Aurinia Pharmaceuticals (AUPH)
TipRanks · 11h ago
Kezar Q1 net loss narrows to $5.8 million; operating loss narrows to $7.4 million
PUBT · 13h ago
Weekly Report: what happened at AUPH last week (0504-0508)?
Weekly Report · 13h ago
RBC Capital Sticks to Their Hold Rating for Aurinia Pharmaceuticals (AUPH)
TipRanks · 3d ago
TD Cowen Reaffirms Their Buy Rating on Aurinia Pharmaceuticals (AUPH)
TipRanks · 4d ago
More
About AUPH
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. It has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct clinical and regulatory activities to support the LUPKYNIS development program. The Company is also developing aritinercept (AUR200), a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases. It sells LUPKYNIS to specialty pharmacies and a specialty distributor in the United States and sells LUPKYNIS inventory to its collaboration partner, Otsuka Pharmaceutical Co., Ltd. (Otsuka), for the European and Japanese market. The Company sells encapsulated voclosporin to its collaboration partner, Otsuka, which Otsuka then sells to customers in its territories.

Webull offers Aurinia Pharmaceuticals Inc stock information, including NASDAQ: AUPH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AUPH stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AUPH stock methods without spending real money on the virtual paper trading platform.